Navigation Links
Arthritis Foundation Announces Appointment of John Vernachio As Vice President of Research
Date:4/15/2013

ATLANTA, April 15, 2013 /PRNewswire-USNewswire/ -- The Arthritis Foundation announces the appointment of John Vernachio , Ph.D. as vice president of research effective April 15. In his new role he will provide leadership and direction to further the Arthritis Foundation research program and the organization's commitment to finding a cure and better, safer treatments for the nation's leading cause of disability. Vernachio will succeed Dr. John Hardin , who will assume a new role within the organization developing and implementing flagship initiatives in osteoarthritis.

(Photo: http://photos.prnewswire.com/prnh/20130415/DC95154 )

" John Vernachio is a world-class scientist and director in biotechnology with a proven track record," says Arthritis Foundation Chief Mission Officer, Jennifer Griffiths , Ph.D.  "I am confident that under his leadership the Arthritis Foundation will continue its legacy in driving targeted research initiatives that will push us toward a cure."

Vernachio brings to the Arthritis Foundation extensive research leadership and expertise, serving as a researcher and technical director in the biotechnology sector for more than 20 years. Most recently, he served as vice president of biology for Inhibitex, Inc.  Earlier, he held supervisory and leadership roles in several biotechnology companies including Baxter Healthcare and Valentis, Inc.  In addition, he is an author on over 20 peer-reviewed scientific articles, numerous scientific presentations and is a co-inventor on 10 patent applications.

A graduate of the University of Vermont, Vernachio earned a Bachelor of Science degree in Animal Science in 1984. He received a doctorate in biochemistry with a concentration in immunology and molecular biology in 1989 from Johns Hopkins University and completed his post-doctoral training in the Department of Immunology at The Research Institute of Scripps Clinic in San Diego in 1991.

About the Arthritis Foundation

Striking one in every five adults and 300,000 children, arthritis is the nation's leading cause of disability.  The Arthritis Foundation (www.arthritis.org) is committed to raising awareness and reducing the unacceptable impact of this serious and painful disease, which can severely damage joints and rob people of living life to its fullest.  The Foundation funds life-changing research that has restored mobility in patients for more than six decades; fights for health care policies that improve the lives of the millions who live with arthritis; and partners with families to provide empowering programs and information.


'/>"/>
SOURCE Arthritis Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. RI Hospital researchers discover new strategy to effectively treat, prevent osteoarthritis
2. Musculoskeletal Network Features New Research into the Cause of Rheumatoid Arthritis and Lupus
3. Targeting T cells in rheumatoid arthritis
4. WISE Surgical Solutions LLC Announces Project Hope: Helping People with Debilitating Conditions Including Arthritis, Parkinson's, MS and Spinal Injury Know Their Options
5. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
6. Musculoskeletal Network Features Update on Nutraceuticals for Osteoarthritis
7. July is not just about BBQ's; the Arthritis National Research Foundation honors Juvenile Arthritis Awareness Month
8. Riding to Cure Arthritis from New York to Oklahoma
9. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
10. Foundation For the NIH Joins NIH In Seeking Proposals to Study Sports-Related Brain Injuries
11. Physicians Endoscopy and Colon Cancer Challenge Foundation Partner to Raise Colon Cancer Awareness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... LAKE, N.J. , Dec. 5, 2016 /PRNewswire/ ... Phase 3 open-label two-year study of rufinamide, which ... the American Epilepsy Society (AES) held from December ... Analysis of final two-year safety, tolerability and cognitive ... with rufinamide experienced similar safety and tolerability profiles, ...
(Date:12/4/2016)...  In five studies being presented today during the ... Exposition in San Diego , researchers ... delivery of life-saving treatments to patients with a variety ... carry therapies directly to the sites in the body ... substantial advantage over traditional, systemic methods. The studies highlight ...
(Date:12/2/2016)... OAKS, Calif. , Dec. 2, 2016 Amgen ... AGN ) today announced the submission of a Marketing ... ABP 215, a biosimilar candidate to Avastin ® (bevacizumab). ... application submitted to the EMA. "The submission ... as Amgen seeks to expand our oncology portfolio," said ...
(Date:12/2/2016)... ... December 01, 2016 , ... Aerocom Healthcare ( ... hospitals, will present its chain-of-custody solution for tracking and securing medications at booth ... Dec. 4-8, 2016. , Aerocom has a proven solution for tracking medications via ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
Breaking Biology News(10 mins):